UiPath (NYSE:PATH) Price Target Raised to $18.00

UiPath (NYSE:PATH) had its target price upped by Bank of America from $16.00 to $18.00 in a research report released on Friday morning, Benzinga reports. The firm currently has a neutral rating on the healthcare company’s stock.

Several other analysts have also commented on PATH. Evercore ISI dropped their price target on shares of UiPath from $27.00 to $13.00 and set an in-line rating on the stock in a research report on Thursday, May 30th. Needham & Company LLC restated a hold rating on shares of UiPath in a research report on Thursday, May 30th. TD Cowen restated a hold rating and set a $17.00 price target (down previously from $28.00) on shares of UiPath in a research report on Thursday, May 30th. Truist Financial restated a hold rating and set a $14.00 price target (down previously from $32.00) on shares of UiPath in a research report on Thursday, May 30th. Finally, Mizuho dropped their price target on shares of UiPath from $25.00 to $14.00 and set a neutral rating on the stock in a research report on Thursday, May 30th. Sixteen equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of Hold and an average price target of $17.71.

UiPath Price Performance

NYSE:PATH opened at $12.19 on Friday. The firm has a market capitalization of $6.98 billion, a P/E ratio of -76.19 and a beta of 0.87. UiPath has a 1-year low of $10.37 and a 1-year high of $27.87. The company’s fifty day moving average price is $12.19 and its 200-day moving average price is $16.54.

UiPath (NYSE:PATH) last released its quarterly earnings data on Thursday, September 5th. The healthcare company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.01. The firm had revenue of $316.00 million for the quarter, compared to analyst estimates of $303.69 million. UiPath had a negative net margin of 8.13% and a negative return on equity of 3.89%. The business’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.09) earnings per share. Equities analysts anticipate that UiPath will post -0.22 EPS for the current fiscal year.

Hedge Funds Weigh In On UiPath

Hedge funds and other institutional investors have recently modified their holdings of the business. Mark Sheptoff Financial Planning LLC purchased a new position in shares of UiPath in the fourth quarter worth about $25,000. ORG Partners LLC lifted its stake in shares of UiPath by 875.6% in the first quarter. ORG Partners LLC now owns 1,239 shares of the healthcare company’s stock worth $27,000 after buying an additional 1,112 shares in the last quarter. Lindbrook Capital LLC lifted its stake in shares of UiPath by 46.0% in the first quarter. Lindbrook Capital LLC now owns 2,027 shares of the healthcare company’s stock worth $46,000 after buying an additional 639 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of UiPath by 40.2% in the first quarter. GAMMA Investing LLC now owns 2,204 shares of the healthcare company’s stock worth $50,000 after buying an additional 632 shares in the last quarter. Finally, Hantz Financial Services Inc. purchased a new position in shares of UiPath in the second quarter worth about $28,000. 62.50% of the stock is owned by hedge funds and other institutional investors.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.